(19)
(11) EP 3 898 675 A1

(12)

(43) Date of publication:
27.10.2021 Bulletin 2021/43

(21) Application number: 19868166.0

(22) Date of filing: 18.12.2019
(51) International Patent Classification (IPC): 
C07K 16/24(2006.01)
A61K 31/282(2006.01)
A61M 5/20(2006.01)
 A61K 39/395(2006.01)
A61P 35/02(2006.01)
A61K 39/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 39/39558; A61K 2039/505; A61M 5/2053; A61P 35/02; C07K 16/245
(86) International application number:
PCT/IB2019/001435
(87) International publication number:
WO 2020/128636 (25.06.2020 Gazette 2020/26)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 21.12.2018 US 201862783568 P

(71) Applicant: Novartis AG
4056 Basel (CH)

(72) Inventors:
  • BRUEDERLE, Andreas
    4002 Basel (CH)
  • WONG, Connie
    Cambridge, MA 02139 (US)
  • VANASSE, K. Gary, J.
    Cambridge, MA 02139 (US)
  • RINNE, Mikael
    Cambridge, MA 02139 (US)
  • REGARD, Jean
    Cambridge, MA 02139 (US)
  • MARATHE, Anshu
    Cambridge, MA 02139 (US)
  • SUN, Haiying
    Hanover, NJ 07936 (US)

(74) Representative: Pfister-Fu, Yixin et al
Novartis Pharma AG Patent Department
4002 Basel
4002 Basel (CH)

   


(54) USE OF IL-1 BETA ANTIBODIES IN THE TREATMENT OR PREVENTION OF MYELODYSPLASTIC SYNDROME